Researchers have successfully demonstrated how an electronic device implanted directly into the brain can detect, stop and even prevent epileptic seizures.
These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications.
The researchers, from the University of Cambridge, the École Nationale Supérieure des Mines and INSERM in France, implanted the device into the brains of mice, and when the first signals of a seizure were detected, delivered a native brain chemical which stopped the seizure from progressing. The results, reported in the journal Science Advances, could also be applied to other conditions including brain tumours and Parkinson’s disease.
The work represents another advance in the development of soft, flexible electronics that interface well with human tissue. “These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications,” said Professor George Malliaras, the Prince Philip Professor of Technology in Cambridge’s Department of Engineering, who led the research.
While there are many different types of seizures, in most patients with epilepsy, neurons in the brain start firing and signal to neighbouring neurons to fire as well, in a snowball effect that can affect consciousness or motor control. Epilepsy is most commonly treated with anti-epileptic drugs, but these drugs often have serious side effects and they do not prevent seizures in three out of 10 patients.
In the current work, the researchers used a neurotransmitter which acts as the ‘brake’ at the source of the seizure, essentially signalling to the neurons to stop firing and end the seizure. The drug is delivered to the affected region of the brain by a neural probe incorporating a tiny ion pump and electrodes to monitor neural activity.
When the neural signal of a seizure is detected by the electrodes, the ion pump is activated, creating an electric field that moves the drug across an ion exchange membrane and out of the device, a process known as electrophoresis. The amount of drug can be controlled by tuning the strength of the electric field.
“In addition to being able to control exactly when and how much drug is delivered, what is special about this approach is that the drugs come out of the device without any solvent,” said lead author Dr Christopher Proctor, a postdoctoral researcher in the Department of Engineering. “This prevents damage to the surrounding tissue and allows the drugs to interact with the cells immediately outside the device.”
The researchers found that seizures could be prevented with relatively small doses of drug representing less than 1% of the total amount of drug loaded into the device. This means the device should be able to operate for extended periods without needing to be refilled. They also found evidence that the delivered drug, which was in fact a neurotransmitter that is native to the body, was taken up by natural processes in the brain within minutes which, the researchers say, should help reduce side effects from the treatment.
Although early results are promising, the potential treatment would not be available for humans for several years. The researchers next plan to study the longer-term effects of the device in mice.
Malliaras is establishing a new facility at Cambridge which will be able to prototype these specialised devices, which could be used for a range of conditions. Although the device was tested in an animal model of epilepsy, the same technology could potentially be used for other neurological conditions, including the treatment of brain tumours and Parkinson’s disease.
The Latest on: Epilepsy
via Google News
The Latest on: Epilepsy
- Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meetingon December 1, 2020 at 6:05 pm
Term Data in Tuberous Sclerosis Complex - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), ...
- 'I didn't know epilepsy drug would harm my son'on December 1, 2020 at 5:23 pm
Christine Coley was prescribed sodium valproate for epilepsy when she was trying for her fourth child but she did not know it risked harming her baby. Her son Tristram is now 22 and has what is known ...
- Unexplained epilepsy death: A son without a dadon December 1, 2020 at 4:03 pm
Lucas, 2, is just one of many New Zealanders to lose a loved one to Sudden Unexplained Death in Epilepsy - the subject of this week's major coronial inquest. A little boy walks to the fridge, reaches ...
- First Guidelines for Keto Diets in Adults With Epilepsy Releasedon December 1, 2020 at 10:41 am
An international panel has developed the first set of recommendations for use of ketogenic diets in adults with epilepsy.
- SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Eventon December 1, 2020 at 5:00 am
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on ...
- Doctors report first case of mirror writing in patient with epilepsyon November 30, 2020 at 10:07 pm
In new research presented at Euroanaesthesia (the annual meeting of the European Society of Anaesthesiology and Intensive Care [ESAIC]), doctors report a highly unusual case of a right-handed patient ...
- Yale study gets closer to understanding causes of severe treatment-resistant epilepsyon November 29, 2020 at 8:27 pm
A recent study by researchers at the Yale School of Medicine found that mice injected with similar gene mutations as humans who have some severe forms of epilepsy also exhibited very similar brain ...
- Global Epilepsy Drugs Market: COVID-19 Impact Analysis| Forecasting Strategies for New Normal | Technavioon November 26, 2020 at 7:01 am
Technavio has announced its latest market research report titled Global Epilepsy Drugs Market 2020-2024 (Graphic: Business Wire) Worried about the impact of COVID-19 on your Business? Here is an ...
- Epilepsy Therapeutic Market Share, Application Analysis, Regional Outlook, Competitive Strategies, Key Players & Forecast up to 2026on November 25, 2020 at 11:48 pm
The Epilepsy Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, ...
- Keto diet therapy recommendations set for adults with epilepsy, other neurologic diseaseson November 25, 2020 at 6:12 am
Johns Hopkins Medicine researchers and others have shown that ketogenic diet therapies—high-fat, low-carbohydrate and adequate protein diets that metabolize fat into chemicals called ketones that ...
via Bing News